Who Owns Moleculin Biotech Stock?
NASDAQ: MBRXHealthcareBiotechnologyUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 8.19%
- Held by insiders
- 6.13%
- Institutional holders
- 23
- Institutions 8.2%
- Insiders 6.1%
- Public and other 85.7%
Who owns Moleculin Biotech stock?
Institutional investors own about 8.2% of Moleculin Biotech's shares, spread across 23 institutions that file 13F reports. That level of institutional ownership is relatively low, leaving more of the stock with retail investors and insiders. Insiders, including executives, directors and large founding shareholders, hold 6.13% of MBRX.
The largest institutional holders are Geode Capital Management, LLC (0.24%), Vanguard Capital Management LLC (0.22%) and Vanguard Fiduciary Trust Co (0.15%). Together, the top 10 institutions control 0.9% of shares outstanding. In their latest filings, 9 of the top 10 institutions increased their MBRX positions and 0 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of MBRX
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Geode Capital Management, LLC | 47.25K | 0.24% | +46.2% |
| Vanguard Capital Management LLC | 42.22K | 0.22% | +204.4% |
| Vanguard Fiduciary Trust Co | 29.88K | 0.15% | +392.1% |
| Xtx Topco Ltd | 22.94K | 0.12% | +100.0% |
| Morgan Stanley | 20.04K | 0.10% | +55555.6% |
| Rockefeller Capital Management L.P. | 15.00K | 0.08% | +239.3% |
| Tower Research Capital LLC (TRC) | 3.51K | 0.02% | +91.5% |
| Citigroup Inc. | 2.67K | 0.01% | +100.0% |
| Barclays Plc | 621 | 0.00% | +100.0% |
| Blackrock Inc. | 491 | 0.00% | 0.0% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of MBRX
| Fund | Shares | % Held |
|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 28.27K | 0.15% |
| Fidelity Concord Street Trust-Fidelity Extended Market Index Fund | 27.44K | 0.14% |
| Fidelity Concord Street Trust-Fidelity Series Total Market Index Fund | 7.99K | 0.04% |
| Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund | 4.48K | 0.02% |
| Fidelity Concord Street Trust-Fidelity Total Market Index Fund | 915 | 0.00% |
Frequently asked questions
Who is the largest shareholder of Moleculin Biotech?
Geode Capital Management, LLC is the largest institutional shareholder of MBRX, owning 0.24% of shares outstanding (47.25K shares) as of its latest 13F filing.
What percentage of Moleculin Biotech is owned by institutions?
Institutions own about 8.2% of MBRX shares and 8.7% of the public float.
How much of Moleculin Biotech do insiders own?
Insiders, such as officers and directors, own about 6.13% of MBRX shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.